How are energy investors positioned?
Investing.com - H.C. Wainwright raised its price target on Oculis Holding AG (NASDAQ:OCS) to $33.00 from $32.00 on Friday, while maintaining a Buy rating on the stock. Currently trading at $17.80, the stock sits within a broader analyst target range of $28.57 to $49.14, according to InvestingPro data.
The price target adjustment follows Oculis’ second-quarter 2025 financial results released Thursday. The company reported grant income of CHF 0.3 million and a net loss of CHF 25.4 million, equivalent to CHF 0.49 per share. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 4.55, though it currently trades above its Fair Value.
Oculis management reaffirmed key upcoming catalysts for its three leading programs, including topline data from Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema expected in the second quarter of 2026, with a new drug application submission planned for the second half of 2026.
The company also confirmed plans to initiate a Phase 2/3 trial of licaminlimab (OCS-02) in dry eye disease in the second half of 2025, and a Phase 2/3 trial of privosegtor (OCS-05) in acute optic neuritis in the first half of 2026.
H.C. Wainwright increased its estimated market value for Oculis to $1.71 billion, approximately $33 per share, supporting the firm’s decision to raise its 12-month price target while maintaining its Buy rating.
In other recent news, Oculis Holding AG has seen significant developments with analyst firms revising their price targets and ratings. Stifel has reiterated its Buy rating on the company, maintaining a price target of $35. This decision is based on progress in Oculis’s late-stage pipeline, particularly highlighting the topical dexamethasone formulation, OCS-01, and the novel compound OCS-05/privosegtor. Meanwhile, Leerink Partners has raised its price target for Oculis from $22 to $50, maintaining an Outperform rating. This upgrade follows discussions with physicians and insights from a recent analyst meeting, emphasizing optimism about Oculis’s developments with the SGK activator, privosegtor. These updates reflect growing confidence in the company’s potential, with attention on its innovative approaches to preventing optic nerve degeneration and neuron death. The recent analyst actions underscore the importance of Oculis’s advancements in its product pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.